Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab

<b>Background/Objectives</b>: The aim of our study was to investigate B cell and T cell responses in people with multiple sclerosis (PwMS) treated with ocrelizumab, a humanized anti-CD20 antibody, who were vaccinated with second and/or booster doses of various vaccine brands against COVID-19. Additi...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Jelena Drulovic, Olivera Tamas, Neda Nikolovski, Nikola Momcilovic, Vanja Radisic, Marko Andabaka, Bojan Jevtic, Goran Stegnjaic, Milica Lazarevic, Nikola Veselinovic, Maja Budimkic, Sarlota Mesaros, Djordje Miljkovic, Tatjana Pekmezovic
Format:	Artigo
Język:	Inglês
Wydane:	MDPI AG 2025-04-01
Seria:	Vaccines
Hasła przedmiotowe:	multiple sclerosis ocrelizumab COVID-19 vaccine response seroconversion
Dostęp online:	https://www.mdpi.com/2076-393X/13/5/488
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!